Maintenance treatment with a gene therapy plus atezolizumab
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1/2 trial tests whether a gene therapy called Reqorsa given with atezolizumab can help people with extensive-stage small cell lung cancer (ES-SCLC) stay controlled after their first chemo. It may help by boosting the immune system to keep the cancer from growing again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re at least 18 years old and have ES-SCLC confirmed by biopsy or fluid testing
- After 3 to 4 cycles of atezolizumab plus carboplatin and etoposide, your scan response is complete response, partial response, or stable disease
- Your energy level is good (ECOG score 0 to 1) and you’re able to follow study visits and instructions
- Recent blood and organ tests are within required ranges (blood counts, kidney, liver) within the last 28 days
- Your heart function is stable, with an ejection fraction of 40% or higher within the last 28 days
- If you have brain metastases, they must be “quiet” (no recent seizures, no recent steroid use, and treatment finished/stable on scans)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with extensive-stage small cell lung cancer. It is for those who have not had treatment for this stage yet.
This trial tests a new study medicine, PF-08634404, combined with chemotherapy for people with extensive-stage small cell lung cancer. It aims to see if this combination works better than standard treatments.
This trial tests a combination of a second course of chemotherapy and an immunotherapy drug (atezolizumab) for people with extensive-stage small cell lung cancer that has returned after initial treatment. The goal is to see if re-using these treatments together can help control the cancer again.
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
This trial tests a new drug (tarlatamab) combined with chemotherapy and immunotherapy for people whose lung cancer has changed from one type (adenocarcinoma) to small cell lung cancer after treatment with EGFR targeted therapy. The goal is to see if this combination is safe and works well.
This study tests a combination of three treatments for extensive-stage small cell lung cancer that has worsened after initial chemotherapy: an experimental pill, focused radiation (SBRT), and an immunotherapy drug. The goal is to see if this triple therapy can help the immune system fight the cancer more effectively.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.